IDEAYA Biosciences Enrolls First Patient for Phase 1 Clinical Trial of IDE892, Targeting MTAP-Deleted Solid Tumors IDEAYA Biosciences has begun its Phase 1 trial for IDE892, a promising PRMT5 inhibitor aimed at treating MTAP-deleted solid tumors, including NSCLC and pancreatic cancer.

IDEAYA Biosciences Enrolls First Patient for Phase 1 Clinical Trial of IDE892, Targeting MTAP-Deleted Solid Tumors #United_States #IDEAYA_Biosciences #South_San_Francisco #PRMT5_Inhibitor #IDE892

IDEAYA Biosciences Submits IND for IDE892, Targeting MTAP-Deleted Solid Tumors IDEAYA Biosciences has submitted an IND application for IDE892, a promising PRMT5 inhibitor aimed at treating MTAP-deleted solid tumors.

IDEAYA Biosciences Submits IND for IDE892, Targeting MTAP-Deleted Solid Tumors #United_States #IDEAYA_Biosciences #South_San_Francisco #PRMT5_Inhibitor #IDE892

Lupin to Present Phase 1 Data on Novel PRMT5 Inhibitor LNP7457 at ASCO 2025 Lupin Limited will unveil results from its Phase 1a trial of LNP7457, a PRMT5 inhibitor, during the ASCO annual meeting, showcasing potential cancer treatment advancements.

Lupin to Present Phase 1 Data on Novel PRMT5 Inhibitor LNP7457 at ASCO 2025 #India #Chicago #PRMT5_Inhibitor #Lupin_Limited #LNP7457

IDEAYA Biosciences Advances Cancer Treatment with New PRMT5 Inhibitor IDE892, Potential Game-Changer in Oncology IDEAYA Biosciences announces IDE892, a promising MTA-cooperative PRMT5 inhibitor, aiming for FDA filing by mid-2025, showcasing significant anti-tumor activity.

IDEAYA Biosciences Advances Cancer Treatment with New PRMT5 Inhibitor IDE892, Potential Game-Changer in Oncology #USA #IDEAYA_Biosciences #South_San_Francisco #PRMT5_Inhibitor #IDE892